159 related articles for article (PubMed ID: 20820745)
1. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
2. Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study.
Pili B; Bourgaux C; Amenitsch H; Keller G; Lepêtre-Mouelhi S; Desmaële D; Couvreur P; Ollivon M
Biochim Biophys Acta; 2010 Aug; 1798(8):1522-32. PubMed ID: 20435013
[TBL] [Abstract][Full Text] [Related]
3. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
5. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
[TBL] [Abstract][Full Text] [Related]
6. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.
Gaudin A; Song E; King AR; Saucier-Sawyer JK; Bindra R; Desmaële D; Couvreur P; Saltzman WM
Biomaterials; 2016 Oct; 105():136-144. PubMed ID: 27521616
[TBL] [Abstract][Full Text] [Related]
7. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
8. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
[TBL] [Abstract][Full Text] [Related]
9. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.
Calvagno MG; Celia C; Paolino D; Cosco D; Iannone M; Castelli F; Doldo P; Frest M
Curr Drug Deliv; 2007 Jan; 4(1):89-101. PubMed ID: 17269921
[TBL] [Abstract][Full Text] [Related]
10. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Immordino ML; Brusa P; Rocco F; Arpicco S; Ceruti M; Cattel L
J Control Release; 2004 Dec; 100(3):331-46. PubMed ID: 15567500
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Brusa P; Immordino ML; Rocco F; Cattel L
Anticancer Res; 2007; 27(1A):195-9. PubMed ID: 17352232
[TBL] [Abstract][Full Text] [Related]
14. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
15. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Celia C; Cosco D; Paolino D; Fresta M
Expert Opin Drug Deliv; 2011 Dec; 8(12):1609-29. PubMed ID: 22077480
[TBL] [Abstract][Full Text] [Related]
17. Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy.
Trung Bui D; Maksimenko A; Desmaële D; Harrisson S; Vauthier C; Couvreur P; Nicolas J
Biomacromolecules; 2013 Aug; 14(8):2837-47. PubMed ID: 23829862
[TBL] [Abstract][Full Text] [Related]
18. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of gemcitabine affinity for biomembranes by conjugation with squalene: differential scanning calorimetry and Langmuir-Blodgett studies using biomembrane models.
Castelli F; Sarpietro MG; Micieli D; Stella B; Rocco F; Cattel L
J Colloid Interface Sci; 2007 Dec; 316(1):43-52. PubMed ID: 17765257
[TBL] [Abstract][Full Text] [Related]
20. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]